Adrian Adams

President & Chief Executive Officer at Impel NeuroPharma, Inc.

Adrian Adams

Adrian Adams

President & Chief Executive Officer at Impel NeuroPharma, Inc.

Overview
Career Highlights

Impel NeuroPharma, Inc.
Aralez Pharmaceuticals, Inc.
POZEN, Inc.

RelSci Relationships

1818

Number of Boards

16

Birthday

1951

Age

70

Contact Data
Trying to get in touch with Adrian Adams? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Adrian Adams likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former President & Chief Business Officer at POZEN, Inc.

Relationship likelihood: Strong

General Counsel & Chief Compliance Officer at Kala Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at POZEN, Inc.

Relationship likelihood: Strong

Co-Founder at Impel NeuroPharma, Inc.

Relationship likelihood: Strong

General Partner at Hatteras Venture Partners

Relationship likelihood: Strong

Chief Medical Officer at Aralez Pharmaceuticals Plc

Relationship likelihood: Strong

Founder at Nicklasson Life Science AB

Relationship likelihood: Strong

Managing Director at GCA Corp. (Japan)

Relationship likelihood: Strong

Chief Executive Officer at Alkermes Plc

Relationship likelihood: Strong

Chief Executive Officer at Synthetic Genomics, Inc.

Relationship likelihood: Strong

Paths to Adrian Adams
Potential Connections via
Relationship Science
You
Adrian Adams
President & Chief Executive Officer at Impel NeuroPharma, Inc.
Education
Undergraduate Degree

The University of Manchester (UoM) is a large research university situated in the city of Manchester, England. Manchester University - as it is commonly known - is a public university formed in 2004 by the merger of the University of Manchester Institute of Science and Technology (est. 1824) and the Victoria University of Manchester (est. 1851). Manchester is a member of the worldwide Universities Research Association group, the Russell Group of British research universities and the N8 Group. The University of Manchester is regarded as a "red brick university", and was a product of the civic university movement of the late 19th century. It formed a constituent part of the federal Victoria University between 1880, when it received its royal charter, and 1903-1904, when it was dissolved. The main campus is south of Manchester city centre on Oxford Road. In 2012, the university had around 39,000 students and 10,400 staff, making it the largest single-site university in the United Kingdom.[5] The University of Manchester had an income of £827 million in 2012–13, of which £200 million was from research grants and contracts.[6] In the 2008 Research Assessment Exercise,[7] Manchester came third in terms of research power and eighth for grade point average quality when including specialist institutions.[8] More students try to gain entry to the University of Manchester than to any other university in the country, with more than 60,000 applications for undergraduate courses.[9] According to the 2012 Highfliers Report, Manchester is the most targeted university by the Top 100 Graduate Employers.[10][11] In the 2012 Academic Ranking of World Universities, Manchester is ranked 40th in the world and 5th in the UK.[12] It is ranked 58th in the world and 12th in Europe in the 2014 Times Higher Education World University Rankings.[13] The university owns and operates major cultural assets such as the Manchester Museum, Whitworth Art Gallery, John Rylands Library and Jodrell Bank Observatory. The University of Manchester has 25 Nobel Laureates among its past and present students and staff, the third-highest number of any single university in the United Kingdom after Cambridge and Oxford. Four Nobel laureates are currently among its staff – more than any other British university.

Career History
President & Chief Executive Officer
2020 - Current

Impel NeuroPharma, Inc. operates as clinical stage biotechnology firm that develops medical devices. It offers intranasal drug treatments for central nervous system (CNS) disorders. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.

Chief Executive Officer & Director
2016 - 2019

Aralez Pharmaceuticals Inc. engages in the development, acquisition, and commercialization of cardiovascular, pain, and other product therapies. It operates through the following geographical segments: United States and Canada. The company is founded on December 2, 2015 and is headquartered in Mississauga, Canada.

Chief Executive Officer, Director
2015 - Prior

POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC.

Boards & Committees
Chairman & Chief Executive Officer
2011 - 2011

Neurologix, Inc. engages in the research, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. The company was founded by Martin J. Kaplitt 1978 and is headquartered in Fort Lee, NJ.

Member, Board of Directors
2007 - 2012

Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA.

Member, Board of Directors
2005 - 2007

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Board Member (Partial Year)
Prior - 2015

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Political Donations
$2,000
2008

Representative from Massachusetts's 2nd Congressional District

$2,300
2007

Representative from Massachusetts's 2nd Congressional District

$2,000
2004

Former President of United States

Transactions
Details Hidden

Impel NeuroPharma, Inc. raised money in a private placement transaction

Details Hidden

Auxilium Pharmaceuticals LLC purchases Actient Pharmaceuticals LLC from GTCR LLC

Details Hidden

Merck & Co., Inc. purchases Inspire Pharmaceuticals, Inc. from Warburg Pincus & Company US LLC

Public Holdings
Restricted data only for RelSci Professional users.
Events
Speaker
New York City, NY
2013 UBS Global Healthcare Conference

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adrian Adams. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adrian Adams's profile does not indicate a business or promotional relationship of any kind between RelSci and Adrian Adams.